(NASDAQ: RNA) Avidity Biosciences's forecast annual revenue growth rate of 126.37% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.84%.
Avidity Biosciences's revenue in 2024 is $10,599,000.On average, 2 Wall Street analysts forecast RNA's revenue for 2024 to be $1,392,830,721, with the lowest RNA revenue forecast at $614,887,823, and the highest RNA revenue forecast at $2,170,773,619. On average, 1 Wall Street analysts forecast RNA's revenue for 2025 to be $3,115,065,633, with the lowest RNA revenue forecast at $3,115,065,633, and the highest RNA revenue forecast at $3,115,065,633.
In 2026, RNA is forecast to generate $14,461,941,999 in revenue, with the lowest revenue forecast at $1,405,457,882 and the highest revenue forecast at $27,518,426,116.